Clear Search sequence regions
Bookmark Forward

QuickView for fenofibrate (compound)


PubChem
Name: Fenofibrate
PubChem Compound ID: 3339
Description: An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Molecular formula: C20H21ClO4
Molecular weight: 360.831 g/mol
Synonyms:
Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; Antara; KBioGR_000706; Lipoclar; KBio1_000557; Triglide; Lipidil; Elasterin; Lopac-F-6020; Prestwick_217.
show more »
DrugBank
Identification
Name: Fenofibrate
Name (isomeric): DB01039
Drug Type: small molecule
Description: An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Synonyms:
Fenofibratum [INN-Latin]; Fenofibrato [INN-Spanish]; Fenofibric acid; Finofibrate; FNF
Brand: Lipantil, Tricor, Lipanthyl, Lipifen, Liposit, Lipidex, Antara, Lipsin, Lipoclar, Elasterate, Lipofene, Fenobrate, Elasterin, Lipirex, Trilipix, Triglide, Sedufen, Fenotard, Protolipan, Secalip, Lipidil Supra, Procetofen, Nolipax, Proctofene, Fenogal, Lofibra, Lipidil Micro, Lipidil, Ankebin, Luxacor
Category: Fribic Acid Derivatives, Antilipemic Agents
CAS number: 49562-28-9
Pharmacology
Indication: For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Pharmacology:
Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult...
show more »
Mechanism of Action:
Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the siz...
show more »
Absorption: Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Protein binding: ~99% (Serum protein binding)
Route of elimination: Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
Half Life: 20 hours
Clearance: 1.2 L/h [Eldery]
Toxicity: LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Increased absorption- take with meals.
Drug interaction:
PravastatinIncreased risk of myopathy/rhabdomyolysis
DicumarolFenofibrate may increase the anticoagulant effect of dicumarol.
AnisindioneFenofibrate may increase the anticoagulant effect of anisindione.
Ursodeoxycholic acidThe fibric acid derivative decreases the effect of ursodiol
RosuvastatinMay cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.
show more »

Targets


Enzymes